Like in ovarian and renal cancers, YAP/TAZ deregulation is a predictor for poor outcomes, indicating involvement in metastatic progression and pharmacotherapy resistance (Luo et al., 2023[84]). This evidence concerns the gene YAP1 and renal carcinoma.